Merck and Eisai announced today that KEYTRUDA®, an anti-PD-1 therapy, in combination with LENVIMA with respective clinical criteria and conditions for adult patients with advanced (not amenable to curativ...
Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma. Katarzyna Kozak, MD, PhD Treatment with eftilagimod alpha plus standard-of-care radiotherapy and pembrolizumab (Keytruda) was shown to be well tolerated and led to ...
also drew attention. In the obese animal model, HM15136 was twice as effective as currently available drugs in weight loss and shown significant body-weight reduction when administered in combination with...
We undertook this analysis of drugs for solid tumour indications to understand if a mechanism for re-evaluation is needed based on the certainty in the evidence available at the time of the HTA recommendations. To measure the certainty in the evidence, we analysed three key factors, if: (1)...